Clinical Trials · NCT00227773

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

WithdrawnPhase 2Octreotide (Prohibited)
Phase
Phase 2
Recruitment status
Withdrawn
Sponsor
Eastern Cooperative Oncology Group
Enrollment
0
Start date
Not specified
Locations
See registry
Primary endpoint
Study in Gastrointestinal Carcinoid Tumor
View Octreotide compound reference